Holen Sie sich die Stockscreener-App
48.66
0.05%
0.035
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by Deutsche Bank AG - MarketBeat
Leerink Partnrs Predicts Lower Earnings for PTC Therapeutics - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Behind the Scenes of PTC Therapeutics's Latest Options Trends - Benzinga
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by Wall Street Zen - MarketBeat
PTC Therapeutics’ SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Ptc Therapeutics, Inc. shares rise 6.59% intraday after presenting at Oppenheimer 28th Annual Tech Conference. - AInvest
Phenylketonuria Market to Witness Promising Upswing by 2034, - openPR.com
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
PTC Therapeutics (PTCT) Is Down 11.4% After Q2 Net Loss Narrows but Six-Month Turnaround Surprises - simplywall.st
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownShould You Sell? - MarketBeat
What makes PTC Therapeutics Inc. stock price move sharplyROI Verified Swing Candidates - sisain.net
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics (NASDAQ:PTCT) Given New $79.00 Price Target at Wells Fargo & Company - MarketBeat
Ptc Therapeutics shares fall 4.19% intraday after announcing executive changes. - AInvest
Earnings Update: PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - uk.finance.yahoo.com
Momentum Screeners Rank PTC Therapeutics Inc. in Top 5 TodayCommunity Strategy With High Win Rate Backtested - metal.it
PTC Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Westfield Capital Management Co. LP Takes $259,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics: Pioneering a New Growth Cycle in Rare Disease Innovation - AInvest
PTC Therapeutics and the Launch of Sephience™: A Catalyst-Driven Play in Rare Disease Innovation - AInvest
Matthew B. Klein Sells 10,739 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Enters Rights Satisfaction Agreement - The Globe and Mail
PTC Therapeutics Announces Q2 2025 Financial Results - The Globe and Mail
PTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches - MSN
Federated Hermes Inc. Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Beat Expectations But Shares Still Dropped - Finimize
PTC Therapeutics price target lowered to $70 from $72 at Baird - TipRanks
Transcript : PTC Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
PTC Therapeutics stock price target raised to $63 from $60 at RBC Capital - Investing.com Canada
PTC Therapeutics stock price target raised to $56 from $52 at TD Cowen - Investing.com Canada
RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating - MarketScreener
PTC Projects Confidence In Sephience Launch With Royalty Buyback - insights.citeline.com
Earnings call transcript: PTC Therapeutics beats Q2 2025 EPS expectations By Investing.com - Investing.com Nigeria
Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating - MarketScreener
Ptc Therapeutics 2025 Q2 Earnings Strong Performance as Net Income Surges 34.6% - AInvest
PTC Therapeutics: Q2 Earnings Snapshot - Greenwich Time
PTC Therapeutics and Evolent Health Receive Bullish Sentiments from Analysts - AInvest
PTC Therapeutics: A Strategic Pivot to Sephience and the Path to Sustained Growth - AInvest
PTC Therapeutics Q2 Loss Narrows, Revenue Declines; Sets Full-Year Revenue Guidance - 富途牛牛
PTC Therapeutics Inc (PTCT) Q2 2025 Earnings Call Highlights: St - GuruFocus
PTC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Reports Q2 2025 Financial Results - TipRanks
PTC Therapeutics Q2 2025 Earnings Preview - MSN
PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions - TipRanks
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC Therapeutics (PTCT): A Strategic Assessment of Growth Catalysts and Profitability Potential Post-Sephience Approval - AInvest
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Citizen Tribune
0.07%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):